14.00
1.35 (10.67%)
| Previous Close | 12.65 |
| Open | 12.35 |
| Volume | 301,103 |
| Avg. Volume (3M) | 243,221 |
| Market Cap | 201,916,000 |
| Price / Sales | 15.80 |
| Price / Book | 3.01 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Operating Margin (TTM) | -981.18% |
| Diluted EPS (TTM) | -9.42 |
| Total Debt/Equity (MRQ) | 32.52% |
| Current Ratio (MRQ) | 9.41 |
| Operating Cash Flow (TTM) | -62.63 M |
| Levered Free Cash Flow (TTM) | -61.34 M |
| Return on Assets (TTM) | -29.82% |
| Return on Equity (TTM) | -60.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Korro Bio, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.70 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.18% |
| % Held by Institutions | 104.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Qiming U.S. Ventures Management, Llc | 30 Sep 2025 | 368,085 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Piper Sandler, 114.29%) | Buy |
| Median | 20.50 (46.43%) | |
| Low | 15.00 (Chardan Capital, 7.14%) | Buy |
| Average | 21.00 (50.00%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 12.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Clear Street | 19 Feb 2026 | 18.00 (28.57%) | Buy | 11.70 |
| Chardan Capital | 29 Jan 2026 | 15.00 (7.14%) | Buy | 13.31 |
| HC Wainwright & Co. | 29 Jan 2026 | 20.00 (42.86%) | Buy | 13.31 |
| Piper Sandler | 29 Jan 2026 | 30.00 (114.29%) | Buy | 13.31 |
| Cantor Fitzgerald | 28 Jan 2026 | 21.00 (50.00%) | Buy | 11.69 |
| Oppenheimer | 28 Jan 2026 | 22.00 (57.14%) | Buy | 11.69 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 11.32 | - | 520 | 5,886 |
| Aggregate Net Quantity | 520 | |||
| Aggregate Net Value ($) | 5,886 | |||
| Aggregate Avg. Buy ($) | 11.32 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 31 Mar 2026 | Buy (+) | 520 | 11.32 | 5,886 |
| Date | Type | Details |
|---|---|---|
| 20 Jan 2026 | Announcement | Korro to Host Virtual Analyst Day on January 27, 2026 |
| 08 Jan 2026 | Announcement | Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |